the fda's gene therapy oversight lost its top regulator amid internal leadership conflict, in the same week that physicians with financial interests in unproven stem cells and peptides were appointed to an advisory panel shaping rules on those products. two independent moves at one agency, both weakening the distance between regulators and the regulated in cutting-edge biologics.